PUT/EVOTEC/15/0.1/20.06.25 Stock

Warrant

DE000GP7BY44

Real-time BOERSE MUENCHEN 08:25:19 2024-07-03 EDT
0.617 EUR -1.91% Intraday chart for PUT/EVOTEC/15/0.1/20.06.25
Current month-4.55%
1 month-6.40%
Date Price Change
24-07-03 0.617 -1.91%
24-07-02 0.629 -0.94%
24-07-01 0.635 -3.64%
24-06-28 0.659 -3.65%
24-06-27 0.684 +5.23%

Real-time BOERSE MUENCHEN

Last update July 03, 2024 at 08:25 am

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GP7BY4
ISINDE000GP7BY44
Date issued 2023-06-29
Strike 15
Maturity 2025-06-20 (352 Days)
Parity 10 : 1
Emission price 0.13
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.775
Lowest since issue 0.126
Delta-0.64x
Omega 0.9769
Premium6.15x
Gearing1.53x
Moneyness 1.591
Difference Strike 5.637
Difference Strike %+37.58%
Spread 0.01
Spread %1.61%
Theoretical value 0.6140
Implied Volatility 64.16 %
Total Loss Probability 15.78 %
Intrinsic value 0.5610
Present value 0.0530
Break even 8.860 €
Theta-0x
Vega0x
Rho-0.01x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.2 EUR
Average target price
20.79 EUR
Spread / Average Target
+125.98%
Consensus